Your browser doesn't support javascript.
loading
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
Wang, Cheng; Ji, Dong; Chen, Jing; Shao, Qing; Li, Bing; Liu, Jialiang; Wu, Vanessa; Wong, April; Wang, Yudong; Zhang, Xiaoyong; Lu, Lei; Wong, Chris; Tsang, Stella; Zhang, Zheng; Sun, Jian; Hou, Jinlin; Chen, Guofeng; Lau, George.
Afiliação
  • Wang C; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Gu
  • Ji D; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China; Liver Failure Treatment and Research Centre, 302 Hospital, Beijing, China.
  • Chen J; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.
  • Shao Q; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China.
  • Li B; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China.
  • Liu J; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China.
  • Wu V; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.
  • Wong A; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.
  • Wang Y; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.
  • Zhang X; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Lu L; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.
  • Wong C; Hong Kong Molecular Pathology Diagnostic Centre, Hong Kong SAR, China.
  • Tsang S; Hong Kong Molecular Pathology Diagnostic Centre, Hong Kong SAR, China.
  • Zhang Z; Institute of Translational Hepatology, 302 Hospital, Beijing, China.
  • Sun J; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Hou J; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Chen G; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China.
  • Lau G; Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China; Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China; Institute of Translational Hepatology, 302 Hospital, Beijing, China. Electronic address: gkklau@netvigator.com.
Clin Gastroenterol Hepatol ; 15(1): 132-136, 2017 01.
Article em En | MEDLINE | ID: mdl-27392759
Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed an observational study to determine the incidence of and factors associated with hepatitis in 327 patients receiving pan-oral DAA agents for HCV infections in areas endemic for HBV in China. Ten patients were positive for hepatitis B surface antigen (HBsAg), and 124 patients had occult HBV infection. HBV reactivation was determined by measuring HBV DNA and HBsAg status in serial serum samples collected every 2 weeks during DAA treatment and then every 4 weeks after treatment until week 12. In the total study population, 10 patients (3.1%) had hepatitis; 3 cases were associated with HBV reactivation (1 case not in the icteric phase, 1 case in the icteric phase, and 1 case with liver failure) and 7 from other causes. Testing positive for HBsAg before DAA treatment was a strong risk factor for developing hepatitis during treatment (hazard ratio, 15.0; P < .001).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Ativação Viral / Hepatite C Crônica / Hepatite B Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Ativação Viral / Hepatite C Crônica / Hepatite B Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2017 Tipo de documento: Article